Open Access

Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial

  • Arman Engheta1,
  • Shahryar Hadadi Abianeh2Email author,
  • Ali Atri1 and
  • Mehdi Sanatkarfar3
DARU Journal of Pharmaceutical Sciences201624:20

DOI: 10.1186/s40199-016-0159-4

Received: 28 May 2016

Accepted: 12 July 2016

Published: 28 July 2016

Abstract

We investigated the occurrence of bleeding complications in patients who underwent skin tumor surgery and compared it between Aspirin users and a placebo control group. In this double blind randomized controlled trial, 32 patients who continued taking aspirin (intervention group) and 38 patients who stopped taking Aspirin (placebo group) before surgery were compared in terms of intraoprative and postoperative bleeding problems, hematoma and local signs of coagulopathy. There was no statistically significant difference in intraoprative bleeding between the study groups (P = 0.107). We concluded that continuation of Aspirin therapy had no significant effect on bleeding complications in patients who underwent skin tumor surgery.

Trial registration

IRCT201602049768N5

Graphical abstract

Flow chart of the study process and its final finding
https://static-content.springer.com/image/art%3A10.1186%2Fs40199-016-0159-4/MediaObjects/40199_2016_159_Figa_HTML.gif

Keywords

Acetyl salicylic acid Skin cancer Surgery Bleeding Complication Aspirin

Discontinuation of anticoagulant or anti platelet agents before skin surgery is still a challenge due to the lack of proper recommendations in the current guidelines [1]. For the decision making, the surgeon should consider several patient-related factors, such as indication of the treatment, patient’s condition and the underlying disease, in order to decide about the continuation or interruption of the drug [2, 3]. Skin surgeries are considered as one of the safest and simplest surgeries. However, rapid increase in the use and new indications of anticoagulant drugs, particularly aspirin, requires specific attention toward their use in skin surgeries [4, 5].

However, the evidence regarding the continuation or discontinuation of Aspirin before skin surgery is inconsistent. In the present study, we aimed to monitor the bleeding complications in patients who underwent skin tumor surgery and compared it between Aspirin users and a placebo control group.

In this double-blind randomized controlled trial, we enrolled patients with non-bleeding skin tumors who were under treatment with aspirin due to any indication. The inclusion criteria were use of Aspirin for at least 3 months before surgery with a daily dose of 80 mg, age between 40 and 75 years, giving an informed consent for taking part in the study, and international normalized ratio (INR) of 1–1.5. Our exclusion criteria included as follows; Having dementia, movement disorder, simultaneous participation in another trial, patients with life-threatening cardiovascular diseases (i.e. New York Heart Association class III or more, history of previous myocardial infarction, severe heart valve disease), bleeding disorders, use of antiplatelets other than Aspirin or anticoagulants and positive history of gastrointestinal bleeding. Moreover, patients who did not follow the prescription rules, those who had a disease that required Aspirin discontinuation or Aspirin intolerance were also excluded. In order to make sure about the drug compliance of the patients, they were asked to bring the blister pack of the consumed tablets.

Using block randomization, patients were randomized into intervention and control groups, matched for age and sex. Both groups were asked to discontinue their Aspirin 7 days before the surgery and they received packed drugs of the trial including Aspirin (80 mg) for the intervention group and placebo for the control group.

Before operation, demographic and baseline clinical characteristics were collected from the patients. The clinical data included the presence of bleeding risk factors, type of skin tumor, number and size of the tumor(s), location of the lesion, drug history and blood test. For every patient, standard resection for the tumor was performed regarding its size and other clinical characteristics. Type of operation and data regarding anesthesia, cautery, need for osteotomy and other surgical characteristics were recorded for the patient. We measured the bleeding by weighing the dressing gases during and after operation up to 24 h. The nurse who was in charge of weighing the gases was blinded to the study protocol. Primary endpoint of the study was the amount of bleeding within and early after surgery. Secondary endpoints were need for early changing of the dressing, development of hematoma or local anticoagulation disorders such as petechia or ecchymosis.

Categorical variables were analyzed by the chi-square test. Continuous variables are presented as means ± standard deviation, or as median and interquartile ranges, as appropriate. Differences between groups in normally and non-normal continuous variables were assessed using the unpaired Student’s t test and the Mann–Whitney U test, respectively. All probability values were two-tailed and a P-value < 0.05 was considered significant. Data were analyzed with Statistical Package for the Social Sciences (SPSS) for Windows, version 15.0 (SPSS Inc., Chicago, Ilinois, United States of America).

In the present study, 38 patients were randomized to the intervention group and 38 patients were included in the control group. However, after randomization it was revealed that three patients had used antiplatelet or anticoagulant drugs and three other patients refused to continue the study; so, they were excluded from the final analysis (n = 32 for the intervention group). The frequency of diabetes and cardiovascular disease was significantly higher in the intervention group (P = 0.009 and P = 0.002, respectively). Details of the demographic and baseline clinical characteristics of the study groups are shown in Table 1.
Table 1

Comparison of the baseline characteristics between the study groups

Characteristica

Intervention (n = 32)

Placebo (n = 38)

P-value

Age, year

65.8 ± 2.3

64.1 ± 1.7

0.218

Male gender, n (%)

24 (75)

29 (76.3)

0.683

Diabetes, n (%)

13 (40.6)

5 (13.2)

0.009

Hypertension, n (%)

23 (71.9)

19 (50)

0.063

Cardiovascular diseases, n (%)

21 (65.6)

11 (28.9)

0.002

Smoking, n (%)

4 (12.5)

5 (13.2)

0.999

Opium abuse, n (%)

3 (9.4)

4 (10.5)

0.999

FBS, mg/dl

123.9 ± 58.0

121.7 ± 44.9

0.696

BUN, mg/dl

37.3 ± 8.9

33.7 ± 8.7

0.064

Creatinine, mg/dl

0.94 ± 0.24

0.95 ± 0.25

0.723

Hemoglobin, g/dl

13.7 ± 1.3

14.9 ± 4.4

0.054

Platelet, 1/mm3

208.4 ± 81.9

200.3 ± 45.1

0.925

INR

2.1 ± 4.7

1 ± 0.01

0.096

PT, sec

13.3 ± 3.2

12.9 ± 2.3

0.001

PTT, sec

28.1 ± 4.1

28.9 ± 3.2

0.114

CT, sec

327.3 ± 72.2

321.7 ± 62.9

0.669

BT, sec

152.7 ± 59.7

148.7 ± 44.6

0.791

BT Bleeding time, BUN Blood urea nitrogen, CT clotting time, FBS Fasting blood sugar, INR International normalized ratio, PT Prothrombin time, PTT Partial thromboplastin time

aVariables are shown as mean ± standard deviation or frequency (percentage) where appropriate

P < 0.05 was considered as statistically significant

Based on the pathology report, characteristics of the tumors and operation were comparable between the two groups as shown in Table 2.
Table 2

Comparison of the tumoral and operative characteristics between the study groups

Characteristica

Intervention (n = 32)

Placebo (n = 38)

P-value

Location

  

0.908

 Face

10 (29.4)

13 (30.9)

 

 Nose

6 (17.6)

4 (9.5)

 

 Ear

4 (11.7)

5 (11.9)

 

 Neck

0 (0)

1 92.3)

 

 Scalp

9 (26.4)

14 (33.3)

 

 Other

5 (14.7)

5 (11.9)

 

Type

  

0.675

 Basal cell carcinoma

24 (75)

32 (84.2)

 

 Squamous cell carcinoma

5 (15.6)

5 (13.2)

 

 Melanoma

1 (3.1)

0 (0)

 

 Not reported

2 (6.2)

1 (2.6)

 

Size of lesion

  

0.17

  < 3 cm

15 (46.9)

14 (35)

 

 3–6 cm

15 (46.9)

24 (60)

 

  > 6 cm

1 (3.1)

2 (5)

 

 Not reported

1 (3.1)

0 (0)

 

Number of lesions

  

0.478

 1 lesion

22 (68.8)

29 (76.3)

 

 2 lesions

3 (9.4)

6 (15.8)

 

 3 lesions

2 (6.2)

1 (2.6)

 

 4 lesions and more

3 (9.4)

1 (2.6)

 

 Not reported

2 (6.2)

1 (2.6)

 

Type of surgery

  

0.72

 Flap

24 (70.6)

28 (68.3)

 

 Graft

9 (56.4)

13 (31.7)

 

 Other

1 (2.9)

0 (0)

 

Type of anesthesia

  

0.999

 Sedative

31 (96.9)

38 (100)

 

 Not reported

1 (3.1)

0 (0)

 

Cautery

  

0.999

 Monopolar

31 (96.9)

37 (97.4)

 

 Bipolar

1 (3.1)

1 (2.6)

 

Need for osteotomy

0 (0)

1 (2.6)

 

Volume of bleeding, ml

30 [20, 80]

30 [17, 40]

0.107

aVariables are shown as frequency (percentage) or median [interquartile range] where appropriate

P < 0.05 was considered as statistically significant

Bleeding in all participants was restricted to the operation time and none of the participants had postoperative bleeding. Median volume of bleeding was 30 gram in both groups (P = 0.107) (Table 2). None of the patients required early change of wound dressing and we observed no case of hematoma or local coagulation disorder.

We found no significant difference between patients who used Aspirin perioperatively and those who discontinued it beforehand. This finding is in line with similar previous studies [68], while the strength of our study is its randomized controlled trial design and its uniform population that consisted of skin cancer patients. We also observed no complication within the study period.

Based on our findings, perioperative Aspirin therapy had no significant effect on bleeding complications in patients who underwent skin tumor surgery. Currently, surgical bleedings can be controlled easily by electrocauterization and are not potentially life-threatening. It seems that dermasurgeons should be more informed about the safety of Aspirin use in skin surgeries based on the current body of knowledge. Larger studies can also contribute to the elucidation of the use of multiple antiplatelet and anticoagulant agents during skin surgeries.

Abbreviations

BT: 

Bleeding time

BUN: 

Blood urea nitrogen

CT: 

Clotting time

FBS: 

Fasting blood sugar

INR: 

International normalized ratio

PT: 

Prothrombin time

PTT: 

Partial thromboplastin time

SPSS: 

Statistical Package for the Social Sciences

Declarations

Acknowledgements

This study was supported by Razi Hospital and Tehran University of Medical Sciences, Tehran, Iran.

Authors’ contribution

Study design: SHA, AA. Randomization, Data collection: AE. Statistical Analysis and drafting: AE, MS. Manuscript revision and final approval: All authors.

Competing interests

The authors declare that they have no competing interests.

Declarations

All participants signed a written informed consent. The protocol of this study was approved by the institutional ethical committee and board of research and is in accordance with the Declaration of Helsinki.

All the authors have read the article and gave consent for its publication as a letter to editor.

Data and material of this study is available via the corresponding author.

This work was funded by Tehran University of Medical Sciences.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Plastic Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences
(2)
Department of Plastic Surgery, Razi Hospital, Tehran University of Medical Sciences
(3)
Department of Anesthesiology, Razi Hospital, Tehran University of Medical Sciences

References

  1. Alam M, Goldberg LH. Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy. Dermatol Surg. 2002;28(11):992–8.PubMedGoogle Scholar
  2. Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg. 2004;30(8):1091–4.PubMedGoogle Scholar
  3. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399–414.View ArticlePubMedGoogle Scholar
  4. Bordeaux JS, Martires KJ, Goldberg D, et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol. 2011;65(3):576–83.View ArticlePubMedGoogle Scholar
  5. Gerstein NS, Schulman PM, Gerstein WH, et al. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg. 2012;255(5):811–9.View ArticlePubMedGoogle Scholar
  6. Eichhorn W, Kluwe L, Heiland M, et al. Lack of evidence for increased risk of postoperative bleeding after cutaneous surgery in the head and neck in patients taking aspirin. Br J Oral Maxillofac Surg. 2014;52(6):527–9.View ArticlePubMedGoogle Scholar
  7. Dixon AJ, Dixon MP, Dixon JB. Bleeding complications in skin cancer surgery are associated with warfarin but not aspirin therapy. Br J Surg. 2007;94(11):1356–60.View ArticlePubMedGoogle Scholar
  8. Dhiwakar M, Khan NA, McClymont LG. Surgical resection of cutaneous head and neck lesions: does aspirin use increase hemorrhagic risk? Arch Otolaryngol Head Neck Surg. 2006;132(11):1237–41.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement